Skip to main content
OpenTrials
Recruiting

NCT Number: NCT06810986

Cohort Study Evaluating Glycaemic Control in Individuals with Type 2 Diabetes Mellitus Through Digital Therapeutics (DM DTx)

This study is conducted to evaluate the effectiveness of Digital therapeutics (DTx) in managing patients with Type 2 Diabetes Mellitus (T2DM) by delivering digital lifestyle interventions through a national health application (BruHealth).

Recruiting

Interested in participating?

Request Info

Key information

Age range

18 year–70 year

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

About this study

This study is a single-arm, non-randomised clinical trial designed to evaluate the effectiveness and feasibility of an online management approach to improve glycaemic control in individuals with Type 2 Diabetes Mellitus (T2DM) through a digital lifestyle intervention (named the BALANCE Programme) over a 16-week period. The intervention leverages the Diabetes Mellitus Digital Therapeutics (DM DTx) module within the BruHealth application. Additionally, a Healthcare Professional (HCP) portal is included to facilitate ongoing monitoring and support, ensuring personalized care and real-time interactions between participants and healthcare providers.

In addition, Muslim participants are offered the option of providing information in the DM DTx module about their fasting practices during Ramadan as an opportunistic way of obtaining data on the fasting risk and fasting experience in this cohort.

Primary Objective:

The primary objective is to assess the proportion of participants who experience a reduction in HbA1c levels by at least 0.6% by the end of the 16-week intervention period.

Secondary Objectives:

  • To evaluate the overall changes in HbA1c, fasting blood glucose, Body Mass Index (BMI), waist circumference and improvements in lipid profile components (such as cholesterol and triglycerides) at week 16, compared to baseline measurements;
  • To evaluate participants' feedback on their experience with the BALANCE Programme and its usability after 16 weeks of usage;
  • to evaluate fasting experience amongst Muslims with T2DM during Ramadhan and to calculate their fasting risk using IDF-DAR score.

Who can participate

Healthy volunteers accepted: No

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • Age 18 to 70 years
  • Diagnosed with T2DM who are on any one or more of the following treatments:
  • oral glucose lowering medication(s)
  • any type of insulin treatment (up to 2 injections a day only)
  • on diet control only
  • GLP-1 receptor agonist established at least 6 months prior to enrolment

Exclusion criteria

  • Diagnosed with T2DM on more than 2 insulin injections a day
  • Diagnosed with Type 1 Diabetes Mellitus (T1DM)
  • Pregnant / Breast-feeding
  • Recent Myocardial Infarction (MI) or Stroke / Cerebrovascular Accidents (CVA) in the past 6 months
  • Heart failure
  • Liver failure
  • Active cancer
  • Undergoing active treatment for active foot disease
  • Undergoing active treatment for active diabetes-related eye disease
  • CKD stage 4 and 5 (eGFR < 30ml/min)
  • Hospitalisation for any reason in the past 6 months
  • Advised by doctor to not participate in intense physical activity
  • Physical disability and/or unable to perform Activities of Daily Living (ADL) independently
  • Unable to use Youtube on mobile devices
  • Unable to use BruHealth independently

Treatment and study plan

16-week digital intervention

Behavioral

Participants will be enrolled in a 16-week programme with the aim to manage T2DM through lifestyle adjustments. Participants will be given online support by their personal health coach with additional support from a dietitian or clinician in the study if required.

Each participant will receive personalised recommendations for blood glucose monitoring schedule, diet and physical activity. Participants are required to log their blood glucose, diet and physical activity in the BruHealth application. Participants will review their progress with their health coach via video consultation on a regular basis. Additionally, participants will also participate in a structured diabetes self-management education course.

Other names: Lifestyle Intervention

Primary outcomes

  1. Reduction in HbA1c from baseline following a 16-week lifestyle intervention

    Time frame: 16 weeks

    The proportion of participants who achieve at least 0.6% reduction in HbA1c from baseline following a 16-week lifestyle intervention provided by DM DTx

Secondary outcomes

  1. Overall change in HbA1c

    Time frame: 16 weeks

    Evaluation of overall changes in HbA1c

  2. Change in fasting lipid profile

    Time frame: 16 weeks

    Evaluation of overall changes in fasting lipid profile

  3. Change in fasting blood glucose

    Time frame: 16 weeks

    Evaluation of overall changes in fasting blood glucose

  4. Change in BMI

    Time frame: 16 weeks

    Evaluation of overall changes in BMI

  5. Change in waist circumference

    Time frame: 16 weeks

    Evaluation of overall changes in waist circumference

  6. Participants' feedback on the use of DM DTx

    Time frame: 16 weeks

    Evaluation of participants' feedback of DM DTx through a series of questionnaires completed on end line

Study contacts

Contact information is provided by the study sponsor or research team.

Jane Tey, Msc Immunology

CONTACT

[email protected]

+673 7430790

Joshua Lam, MBBS

CONTACT

[email protected]

+65 97309276

Sponsors and collaborators

Lead sponsor

EVYD Technology

Industry

Collaborators

  • Ministry of Health, Brunei Darussalam

Registry information

Official study title

Phase 2 Research Study for Type 2 Diabetes Mellitus Through Digital Therapeutics

Acronym: DM DTx

Important dates

Study start
2024
Primary completion
2025
Study completion
2025
First posted
Feb 6, 2025
Registry last updated
Feb 6, 2025

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Published trials that share one or more normalized conditions with this study.